A Phase 2 Open-Label Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 years of age with CLN2 Disease
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Cerliponase alfa (Primary)
- Indications Neuronal ceroid lipofuscinosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 10 Jun 2017 Biomarkers information updated
- 12 May 2017 Planned End Date changed from 1 Jun 2018 to 1 Dec 2022.
- 12 May 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2022.